Small molecule · developed by Atossa Therapeutics
Endoxifen is an oral (Z)-endoxifen capsule studied at doses of 20 mg, 40 mg and 80 mg. It is being evaluated in breast cancer, including estrogen-receptor-positive and HER2-negative disease, and in mammographic breast density.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05607004 | Phase 2 | Breast Neoplasms | Active not recruiting | ATOS |
| NCT04616430 | Phase 2 | Mammographic Breast Density | Completed | ATOS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Breast NeoplasmsEstrogen-receptor-positive Breast CancerHER2-negative Breast CancerInvasive Breast CancerMammographic Breast Density
Updated Oct 11, 2026. Something wrong or missing? Report it on the ATOS page.
See ATOS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ATOS catalysts and pipeline →